Thyroid-stimulating hormone stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo

Gagnon, AnneMarie; Antunes, Tayze T.; Ly, Tapraya; Pongsuwan, Patama; Gavin, Claire; Lochnan, Heather; Sorisky, Alexander

doi:10.1016/j.metabol.2009.08.018

Cited by 70 publications

(70 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an in vivo experiment, in a mouse model, mice with elevated TSH exhibited a 25% increase in adipose tissue when compared to control animals with normal TSH [26]. On the other hand, TSH activates hormone-sensitive lipase and lipolysis; therefore, elevated levels of TSH are connected with raising serum free fatty acids [27]. Increased serum FFA concentrations have been observed in subclinical hypothyroid patients and could lead to insulin resistance [28].…”

Section: Prace Oryginalnementioning

confidence: 99%

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Siemińśka

Wojciechowska

Walczak

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: The prevalence of metabolic syndrome increases after menopause; however, the role of concomitant subclinical hypothyroidism has not been completely elucidated. The aim of the study was to identify associations between thyrotropin, immune status, inflammation, and metabolic syndrome in postmenopausal women. The specific goals were: to assess thyrotropin (TSH) and interleukin-6 (IL-6) concentrations in the serum of subclinical hypothyroid postmenopausal women with and without metabolic syndrome and compare them with euthyroid controls; to test whether immune status is related to metabolic syndrome in postmenopausal women and determine the role of IL-6; to examine the relationships between TSH and different features of metabolic syndrome: insulin resistance, waist circumferences, waist-to-hip ratio (WHR), BMI, metabolic parameters (triglycerides, total cholesterol and high-density lipoprotein cholesterol), and inflammatory cytokines (IL-6). Material and methods: Three hundred and seventy-two postmenopausal women were included in the study: 114 women had subclinical hypothyroidism (10.0 uIU/mL > TSH ≥ 4.5 uIU/mL, normal fT4), and 258 women were in euthyreosis (TSH 0.35-4.5 uIU/mL, normal fT4); both groups were matched by age. Anthropometric measurements were conducted (BMI, waist circumference, WHR) and blood pressure was measured. In all subjects the following were assessed in serum: lipid profile, glucose, insulin, TSH, fT4, thyroid antibodies (T-Abs) -TPO-Abs, TG-Abs, and IL-6 concentrations. Results: The prevalence of metabolic syndrome was 49.12% in subclinical hypothyroid women and 46.89% in euthyroid women. However, the proportion of subjects with one or two abnormalities was significantly higher in the subclinical hypothyroid group (45.61%) than in the euthyroid group (32.17%). When we compared subclinical hypothyroid women with and without metabolic syndrome, subjects with metabolic syndrome had higher BMI, abdominal circumferences, WHR, and HOMA-I. They presented higher systolic and diastolic blood pressure. Serum concentrations of cholesterol, triglycerides, fasting glucose, IL-6, TSH, T-Abs were also higher and serum cHDL was lower. There were no significant differences in fT4 concentrations. A similar comparison was made for euthyroid women with and without metabolic syndrome. Higher BMI, waist circumference, WHR, HOMA-I, and systolic blood pressure were observed in subjects with metabolic syndrome. Serum concentrations of TSH, triglycerides, glucose, and IL-6 were also higher, but the concentration of cHDL was significantly lower. There were no significant differences in fT4, T-Abs, cholesterol levels, and diastolic pressure. When we compared euthyroid women T-Abs (+) and T-Abs (-), the prevalence of metabolic syndrome was similar (48.68% vs. 46.15%). There were no differences in BMI, waist circumference, WHR, lipid profile, glucose, and HOMA-I, fT4. However, thyroid autoimmunity was associated with elevated TSH and IL-6 levels. When we analysed subclinical hypothyroid women with ...

show abstract

Section: Prace Oryginalnementioning

confidence: 99%

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Siemińśka

Wojciechowska

Walczak

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…Morning blood samples were obtained on days 1 (prior to the rst dose of rhTSH), 3 and 5. Separate aliquots of blood from 19 of these patients had been used previously to assess FFA levels [8]. Fetuin-A was measured using the Human Fetuin-A uantikine ELISA kit (R&D Systems), as per manufacturer's instructions.…”

Section: Patients and Blood Samplingmentioning

confidence: 99%

“…x 2 daily doses) with serial blood sampling for thyroglobulin over 5 days. Using this particular experimental paradigm, rhTSH has been shown to increase serum levels of IL-6 and FFA in vi o [7,8], and to increase IL-6, TNFα, lipoperoxide and leptin levels [9,10].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Serum fetuin-A levels following recombinant human thyroid-stimulating hormone stimulation

Gagnon¹,

Abujrad²,

Irobi

et al. 2013

CIM

Self Cite

View full text Add to dashboard Cite

Purpose: Fetuin-A is a hepatokine that is linked to lipid metabolism, obesity, insulin resistance, type 2 diabetes and cardiovascular disease. Elevated thyroid-stimulating hormone (TSH) levels are associated with metabolic and cardiovascular disturbances. Our aim was to determine if TSH can regulate fetuin-A levels.Methods: Fetuin-A serum levels were examined in 26 subjects (19 women; previous thyroidectomy and radioactive iodine ablation) undergoing recombinant human TSH (rhTSH) stimulation to screen for thyroid cancer recurrence. eir age was 49±10 years, and body mass index (BMI) was 28±6 (both expressed as mean±SD). e patients received two doses of rhTSH (0.9 mg), administered 24 hours apart on days 1 and 2, without discontinuation of ongoing L-thyroxine therapy. Morning blood samples were obtained on days 1 (prior to the rst dose of rhTSH), 3 and 5.Results: e baseline value of fetuin-A (mean±SD) for all participants was 527±186 mg/ L. Values of fetuin-A did not change in response to rhTSH administration. e lack of response was not dependent on gender, age, baseline free thyroxine level or BMI.Conclusion: Fetuin-A has been implicated in metabolic and in ammatory conditions, but there have been no reports on whether fetuin-A is in uenced by TSH. Within the context of rhTSH administration for surveillance of thyroid cancer recurrence, there was no e ect on serum levels of fetuin-A.

show abstract

“…Tian et al (27) proposed that TSH upregulates the expression of hepatic 3-hydroxy-3-methyl-glutaryl co-enzyme A reductase (an enzyme that limits cholesterol synthesis) by acting on the TSH receptor on liver cells. Gagnon et al (28) showed that TSH stimulates lipolysis in cultured adipocytes and elevates serum-free fatty acid levels. The elevated TSH levels in the serum of patients with SH suggest that, although apparently normal, serum thyroid hormones are insufficient.…”

Section: Discussionmentioning

confidence: 99%

Subclinical Hypothyroidism is Associated with Atherogenic Lipid Profile in Postmenopausal Women

Godinjak¹,

Velija-Ašimi²,

Bureković³

et al. 2017

Turk J Endocrinol Metab

View full text Add to dashboard Cite

IntroductionSubclinical hypothyroidism (SH) is defined as an elevated serum level of thyroid stimulating hormone (TSH) with the normal levels of free thyroxine (FT4) and free triiodothyronine (FT3) (1). Most patients are symptomless and have serum TSH levels <10 mU/L. In the studies conducted on the general population, the prevalence of subclinical hypothyroidism ranges from 4% to 15% (2). The preva-37 S Su ub bc cl li in ni ic ca al l H Hy yp po ot th hy yr ro oi id di is sm m i is s A As ss so oc ci ia at te ed d w wi it th h A At th he er ro og ge en ni ic c L Li ip pi id d P Pr ro ofi fil le e i in n P Po os st tm me en no op pa au us sa al l W Wo om me en n Purpose: To determine the prevalence and association of atherogenic lipid profile in postmenopausal women with subclinical hypothyroidism. Materials (Subjects) and Methods: This as a prospective clinical study included 140 postmenopausal women. In all subjects, basic sociodemographic and anthropometric data, hormonal status of the thyroid gland, and lipid profile were determined. The subjects were followed for a period of 30 months.Results: The subclinical hypothyroidism in postmenopausal women was significantly associated with higher levels of serum cholesterol, triglycerides, LDL-C, and lower HDL-C (p=0.009, p=0.01, p=0.023, p=0.001, respectively). Furthermore, the analysis of repeated measures showed that subclinical hypothyroidism, irrespective of age and duration of postmenopause, was associated with higher levels of serum cholesterol (

show abstract

Thyroid-stimulating hormone stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo

Cited by 70 publications

References 30 publications

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Powiązania między zespołem metabolicznym, subkliniczną niedoczynnością i autoimmunologicznym zapaleniem tarczycy u kobiet po menopauzie oraz rola interleukiny-6

Serum fetuin-A levels following recombinant human thyroid-stimulating hormone stimulation

Subclinical Hypothyroidism is Associated with Atherogenic Lipid Profile in Postmenopausal Women

Contact Info

Product

Resources

About